Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine

被引:17
作者
Merello, M
Perez-Lloret, S
Antico, J
Obeso, JA
机构
[1] FLENI, Movement Disorders Sect, Raul Carrea Inst Neurol Res, Buenos Aires, DF, Argentina
[2] Univ Navarra, Dept Neurol & Neurosurg, Univ Clin & Med Sch, E-31080 Pamplona, Spain
[3] FIMA, Pamplona, Spain
关键词
D O I
10.1136/jnnp.2005.068940
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Dyskinesias are a transient but severe complication of subthalamotomy in some patients. Patients and methods: Three patients with Parkinson's disease undergoing bilateral micro-recording guided surgery of the subthalamic nucleus (STN) are described; deep brain stimulation (DBS) was used in one case, and subtkalamotomy in the other two. Prior to surgery, levodopa induced dyskinesia had improved (<= 50%) under treatment with amantadine (400 mg/day, po) in all three patients. The patient treated with DBS developed severe dyskinesia a few days after discharge and began self medication with amantacline but showed no improvement. This suggested a possible lack of response to amantacline for treatment of dyskinesias induced by surgery of the STN. Results: Both patients treated with bilateral subthalamotomy developed unilateral choreoballistic movements immediately after surgery, despite not taking levodopa (L-dopa). Patients were scored using the dyskinesia scale and started treatment with 400 mg amantadine (po) for 4 days within the first postoperative week with no effect on dyskinesia score or its phenomenology. Amantadine was therefore discontinued. One month after surgery both patients were free of involuntary movements with an improvement of about 60% in the "off" state UPDRS motor score. Six month follow up showed maintained antiparkinsonian benefit, without need for levodopa treatment and complete absence of dyskinesia. Conclusion: The present findings suggest that: (i) amantacline probably exerts its anti-dyskinetic effect by acting on the "indirect" pathway; 60 the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L-dopa induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop.
引用
收藏
页码:172 / 174
页数:3
相关论文
共 18 条
[1]   MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson's disease [J].
Allers, KA ;
Bergstrom, DA ;
Ghazi, LJ ;
Kreiss, DS ;
Walters, JR .
EXPERIMENTAL NEUROLOGY, 2005, 191 (01) :104-118
[2]   Bilateral subthalamotomy in Parkinson's disease: initial and long-term response [J].
Alvarez, L ;
Macias, R ;
Lopez, G ;
Alvarez, E ;
Pavon, N ;
Rodriguez-Oroz, MC ;
Juncos, JL ;
Maragoto, C ;
Guridi, J ;
Litvan, I ;
Tolosa, ES ;
Koller, W ;
Vitek, J ;
DeLong, MR ;
Obeso, JA .
BRAIN, 2005, 128 :570-583
[3]   Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease [J].
Blanchet, PJ ;
Papa, SM ;
Metman, LV ;
Mouradian, MM ;
Chase, TN .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (04) :447-453
[4]   ALLEVIATION OF PARKINSONISM BY ANTAGONISM OF EXCITATORY AMINO-ACID TRANSMISSION IN THE MEDIAL SEGMENT OF THE GLOBUS-PALLIDUS IN RAT AND PRIMATE [J].
BROTCHIE, JM ;
MITCHELL, IJ ;
SAMBROOK, MA ;
CROSSMAN, AR .
MOVEMENT DISORDERS, 1991, 6 (02) :133-138
[5]  
Calabresi P, 2000, ANN NEUROL, V47, pS60
[6]   Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease [J].
Calon, F ;
Rajput, AH ;
Hornykiewicz, O ;
Bédard, PJ ;
Di Paolo, T .
NEUROBIOLOGY OF DISEASE, 2003, 14 (03) :404-416
[7]   NEUROMODULATORY ACTIONS OF DOPAMINE IN THE NEOSTRIATUM ARE DEPENDENT UPON THE EXCITATORY AMINO-ACID RECEPTOR SUBTYPES ACTIVATED [J].
CEPEDA, C ;
BUCHWALD, NA ;
LEVINE, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (20) :9576-9580
[8]   Hemiballism after subthalamotomy in patients with Parkinson's disease: Report of 2 cases [J].
Chen, CC ;
Lee, ST ;
Wu, T ;
Chen, CJ ;
Huang, CC ;
Lu, CS .
MOVEMENT DISORDERS, 2002, 17 (06) :1367-1371
[9]   Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies [J].
Danysz, W ;
Parsons, CG ;
Kornhuber, J ;
Schmidt, WJ ;
Quack, G .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (04) :455-468
[10]  
Defer GL, 1999, MOVEMENT DISORD, V14, P572, DOI 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO